Abstract
Thermogravimetry (TG) and differential scanning calorimetry (DSC) are useful techniques that have been successfully applied in the pharmaceutical industry to reveal important information regarding the physicochemical properties of drugs and excipient molecules, such as polymorphism, stability, purity, formulation compatibility, among others. AMI presents a thermal stability of up to 431 K and a fusion onset temperature of 432 K. The drug has proven to be incompatible with magnesium stearate, eskis red pigment, and yellow iron oxide. In the present study, this drug presented degradation upon undergoing basic hydrolysis and oxidation; the degradation product produced under basic hydrolysis is 2-butyl-3-benzofuranyl-3,4-dihydroxy-5-iodophenylketone. Assessing the degradation kinetics, the drug presented a shelf life (t90) of 43 years, while a pharmaceutical formulation showed a t90 of 1.7 years, which is consistent with commonly understood incompatibilities in pharmaceutical formulations.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
